Prognostic significance of tumor location in high-grade non-muscle-invasive bladder cancer

The management of high-grade (HG) non-muscle-invasive bladder cancer (NMIBC) continues to be a serious clinical problem. The role of many factors related to efficacy of Bacillus Calmette-Guérin (BCG), which is the most useful intravesical agent for these tumors, is still unknown. This study investig...

Full description

Saved in:
Bibliographic Details
Published in:Medical oncology (Northwood, London, England) London, England), 2012-09, Vol.29 (3), p.1916-1920
Main Authors: Vukomanovic, Ivana, Colovic, Vidosav, Soldatovic, Ivan, Hadzi-Djokic, Jovan
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Carcinoma in Situ - pathology
Carcinoma, Transitional Cell - pathology
Female
Hematology
Humans
Internal Medicine
Male
Medicine
Medicine & Public Health
Middle Aged
Neoplasm Grading
Neoplasm Recurrence, Local - epidemiology
Neoplasm Recurrence, Local - pathology
Neoplasm Staging
Oncology
Original Paper
Pathology
Prognosis
Urinary Bladder Neoplasms - pathology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The management of high-grade (HG) non-muscle-invasive bladder cancer (NMIBC) continues to be a serious clinical problem. The role of many factors related to efficacy of Bacillus Calmette-Guérin (BCG), which is the most useful intravesical agent for these tumors, is still unknown. This study investigated the prognostic value of tumor location in high-grade non-muscle-invasive bladder cancer. Seventy-four patients with HG non-muscle-invasive bladder cancer, without carcinoma in situ (CIS), were treated by transurethral resection of bladder tumor (TURBT). Twenty-eight patients received adjuvant BCG therapy after TURBT. The relation between tumor location and the recurrence capacity was estimated using a Cox regression model. Our results suggest that tumor location is an important prognostic factor for BCG-therapy response in patients with high-grade non-muscle-invasive bladder cancer. Tumors in the bladder neck might have a higher risk of recurrence after intravesical immunotherapy. In addition, tumors in the lateral and posterior bladder walls might be at higher risk of recurrence when treated by TURBT alone.
ISSN:1357-0560
1559-131X
DOI:10.1007/s12032-011-9999-4